Skip to main content

Utilization of Select Biological Products: A Descriptive Analysis

    Basic Details
    Date Posted
    Monday, March 20, 2023
    Medical Product
    Avastin (bevacizumab)
    Epogen (epoetin alfa)
    Inflectra (infliximab-dyyb)
    Mvasi (bevacizumab-awwb)
    Neupogen (filgrastim)
    Remicade (infliximab)
    Renflexis (infliximab-abda)
    Retacrit (epoetin alfa-epbx)
    Zarxio (filgrastim-sndz)
    Zirabev (bevacizumab-bvzr)

    In this report, we examined utilization patterns of certain biological products (Avastin, Epogen, Inflectra, Mvasi, Neupogen, Remicade, Renflexis, Retacrit, Zarxio, Zirabev). The study period includes data from October 1, 2015 to June 30, 2021. The request was executed on Merative™ MarketScan® Research Databases on June 10, 2022.

    Additional Details
    FDA Center
    Time Period
    October 1, 2015 - June 30, 2021
    Study Type
    Query Builder
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Merative™ MarketScan® Research Databases